• Markets
    • icon
  • Companies
MSB · ASX

Mesoblast Limited (ASX:MSB)

AU$0.4

 0.0 (0.0%)
ASX:Live
01/12/2023 12:00:00 AM
Volume Spike Short Sold <-1 over the month HALO Small HALO Ords HALO Earnings Momentum +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

MSB Overview

MSB Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About MSB

Website

Mesoblast Limited

Telephone

61.3.9639.6036

Address

Level 38 55 Collins Street Melbourne, Victoria (VIC) 3000

Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

MSB Price Chart

Key Stats

Market Cap

AU$329.75M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.34 - 1.42

Trade Value (12mth)

US$345,215.00

1 week

5.19%

1 month

10.96%

YTD

-53.18%

1 year

-63.35%

All time high

9.93926

Key Fundamentals

EPS 3 yr Growth

-24.800%

EBITDA Margin

-915.70%

Operating Cashflow

-$69m

Free Cash Flow Return

-11.60%

ROIC

-13.70%

Interest Coverage

-3.40

Quick Ratio

1.90

Other Data

Shares on Issue (Fully Dilluted)

746m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

6.76

MSB Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 May 22

Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients

×

Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients

31 May 22

Mesoblast Q3 Financial Results Webcast

×

Mesoblast Q3 Financial Results Webcast

31 May 19

Third Quarter Results Presentation

×

Third Quarter Results Presentation

31 May 18

Third Quarter Results Presentation

×

Third Quarter Results Presentation

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 22

Appendix 4C Quarterly Activity Report

×

Appendix 4C Quarterly Activity Report

31 December 21

Update on FDA Meeting for Remestemcel-L in Paediatric GvHD

×

Update on FDA Meeting for Remestemcel-L in Paediatric GvHD

31 August 23

Preliminary Final Report including Appendix 4E

×

Preliminary Final Report including Appendix 4E

31 August 23

Annual Financial Results Presentation

×

Annual Financial Results Presentation

31 August 23

MSB Annual Financial Results and Operational Update

×

MSB Annual Financial Results and Operational Update

31 August 22

Preliminary Final Report

×

Preliminary Final Report

31 August 22

Annual Financial Results Presentation

×

Annual Financial Results Presentation

31 August 22

MSB Annual Financial Results and Operational Highlights

×

MSB Annual Financial Results and Operational Highlights

31 August 21

Annual Financial Results Presentation

×

Annual Financial Results Presentation

31 August 21

MSB Annual Financial Results and Operational Progress

×

MSB Annual Financial Results and Operational Progress

30 October 23

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

30 October 23

Notice of Annual General Meeting and Proxy Form

×

Notice of Annual General Meeting and Proxy Form

30 October 23

Annual Report to Shareholders

×

Annual Report to Shareholders

30 October 18

Annual Report to shareholders

×

Annual Report to shareholders

30 November 18

Presentation to 2018 Annual General Meeting

×

Presentation to 2018 Annual General Meeting

30 November 09

Executive Director`s Presentation to AGM

×

Executive Director`s Presentation to AGM

30 May 22

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

30 March 20

Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting

×

Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting

30 August 22

Mesoblast 2022 Full Year Financial Results Webcast

×

Mesoblast 2022 Full Year Financial Results Webcast

MSB Fundamentals

Per Share Records

Historical data

Forecasted data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.16 -0.14 -0.11 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.16 -0.14 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 13.8 21.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.15 -0.12 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.18 -0.11 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.4 22.1 30.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -12.1 -25.1 -12.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.90 0.76 0.62 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 -0.13 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 102.4 -9,660.3 26.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 605 649 739 Lock Lock Lock
Basic m Lock Lock Lock Lock 605 649 739 Lock Lock Lock

Financial Records

Historical data

Forecasted data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 7 10 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -76.5 37.4 -26.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 84 60 53 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -25 -21 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -501.0 18.7 1.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -340.1 -201.2 -269.7 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 440 301 370 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -105 -76 -69 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.0 27.4 9.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,411.1 -746.2 -915.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 4 4 4 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -109 -81 -73 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.6 26.2 9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,468.4 -789.1 -970.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -100 -92 -86 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -99 -91 -82 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.8 7.6 10.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,329.2 -894.6 -1,091.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -107 -72 -69 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 2 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -2 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 114 -4 81 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -108 -72 -70 Lock Lock Lock
     Growth % Lock Lock Lock Lock -85.3 33.5 3.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -14.6 -7.1 -9.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 137 60 71 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 825 750 669 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 50 99 106 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -31 46 45 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 243 253 168 Lock Lock Lock
Equity $m Lock Lock Lock Lock 578 524 507 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 631 596 608 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.0 -5.6 2.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.0 -12.2 -12.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.1 -17.4 -16.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -15.8 -12.4 -12.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -15.3 -14.8 -13.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -16.5 -11.6 -11.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

USD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -6.6 -4.4 -3.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.3 -0.6 -0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -5.4 8.9 8.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.6 1.4 1.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.6 1.4 1.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 92.3 86.6 87.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -113.2 -139.9 -165.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.3 2.2 1.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.5 0.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 261.9 238.4 271.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,340.2 -896.9 -1,141.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.1 -12.2 -12.8 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.0 -12.2 -12.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.4 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -17.1 -17.4 -16.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -17.1 -17.4 -16.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 160.0 166.6 276.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 160.0 166.6 276.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 259.5 256.8 282.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -99.6 -90.2 -5.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.76%

Value ($M)

22

Prior Change

-1.00%

7 Day Change

-1.30%

1 Month Change

-1.30%

3 Month Change

-0.50%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MSB Shortsell

Frequently Asked Questions

The current share price of Mesoblast Limited (MSB:ASX) is AU$0.4.
The 52-week high share price for Mesoblast Limited (MSB:ASX) is AU$1.42.
The 52-week low share price for Mesoblast Limited (MSB:ASX)? is AU$0.34.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) does not pay a dividend.
Mesoblast Limited (MSB:ASX) has a franking level of 0%.
Mesoblast Limited (MSB:ASX) is classified in the Healthcare.
The current P/E ratio for Mesoblast Limited (MSB:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.